(Q42196891)

English

The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

author name string

N Cascinelli

1

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

P Rümke

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

R MacKie

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

A Morabito

4

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

R Bufalino

5

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

publication date

1 January 1989

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

282-286

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Tumor thickness as a guide to surgical management of clinical stage I melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BCG induced CD4+ cytotoxic T cells from BCG vaccinated healthy subjects: relation between cytotoxicity and suppression in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant chemotherapy in the management of primary malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a nonrandomized trial in malignant melanoma patients (Clark's stages III--V) treated by post-surgical chemoimmunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with BCG adjuvant immunotherapy in stage II malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant chemoimmunotherapy stage I/II malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bacillus Calmette-Guerin immunotherapy for bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant Therapy for Malignant Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of cancer. Present Status and Future Potential

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Active immunotherapy with B.C.G. for recurrent malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Shared antigens between human malignant melanoma cells and Mycobacterium bovis (BCG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Intranodular treatment with BCG of cutaneous and subcutaneous metastases of malignant melanoma (author's transl)].

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee.

1 reference

https://pubmed.ncbi.nlm.nih.gov/2702680

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00205238

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42196891&oldid=2205111573"